GV
GPN Vaccines
Australia · Biotech
GPN Vaccines develops bacterial vaccines designed to protect against a broader range of strains than conventional serotype-specific vaccines.
Product
GPN Vaccines works from New York and Adelaide on vaccines for bacterial diseases. Its lead candidate, Gamma-PN, is a whole-cell pneumococcal vaccine designed to generate protection across serotypes.
The company is preparing Gamma-PN for Phase 2 development after four Phase 1 studies. Its broader pipeline includes a Streptococcus suis programme and additional bacterial vaccine programmes through BacVax.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Private placement | $10M | Participants not disclosed |